Mineral Nanomedicine to Enhance the Efficacy of Adjuvant Radiotherapy for Treating Osteosarcoma

Yu-Chi Wang,Sheng-han Tsai,Ming-Hong Chen,Fu-Yu Hsieh,Yuan-Chen Chang,Fu-I Tung,Tse-Ying Liu
DOI: https://doi.org/10.1021/acsami.1c21729
2022-01-20
Abstract:It is vital to remove residual tumor cells after resection to avoid the recurrence and metastasis of osteosarcoma. In this study, a mineral nanomedicine, europium-doped calcium fluoride (CaF<sub>2</sub>:Eu) nanoparticles (NPs), is developed to enhance the efficacy of adjuvant radiotherapy (i.e., surgical resection followed by radiotherapy) for tumor cell growth and metastasis of osteosarcoma. <i>In vitro</i> studies show that CaF<sub>2</sub>:Eu NPs (200 μg/mL) exert osteosarcoma cell (143B)-selective toxicity and migration-inhibiting effects at a Eu dopant amount of 2.95 atomic weight percentage. These effects are further enhanced under X-ray irradiation (6 MeV, 4 Gy). Furthermore, <i>in vivo</i> tests show that intraosseous injection of CaF<sub>2</sub>:Eu NPs and X-ray irradiation have satisfactory therapeutic efficacy in controlling primary tumor size and inhibiting primary tumor metastasis. Overall, our results suggest that CaF<sub>2</sub>:Eu NPs with their osteosarcoma cell (143B)-selective toxicity and migration-inhibiting effects combined with radiotherapy might be nanomedicines for treating osteosarcoma after tumor resection.
materials science, multidisciplinary,nanoscience & nanotechnology
What problem does this paper attempt to address?